Welcome to our dedicated page for Fuse Group news (Ticker: FUST), a resource for investors and traders seeking the latest updates and insights on Fuse Group stock.
Fuse Group Holding Inc. (FUST) is a Nevada-incorporated company whose common stock trades on the OTCQB market. In its public announcements, the company has described itself as being in development of business in the mining and biotech areas, while also pursuing consulting, marketing and business development work for other businesses.
The news flow around Fuse Group Holding Inc. highlights two main themes. First, the company has reported steps toward entering biotech research and development through its wholly owned subsidiary Fuse Biotech Inc., which entered into a non-binding letter of intent to acquire E-Mo Biotech Holding Inc. E-Mo is described as being involved in biology research and development related to vaccines, immunological treatment, diagnostic product development and similar treatments against SARS-CoV-2 and relevant diseases.
Second, Fuse Group has announced a consulting agreement with Beijing Jixiang Fengqi Tech Company Limited, an IT consulting and digital marketing services firm. Under this arrangement, Fuse Group agreed to provide general consulting, marketing and business development services, including marketing research, competitive analysis and digital marketing implementation, to support Beijing Jixiang’s expansion in the North American market.
Visitors to this news page can review company-issued updates on topics such as potential biotech acquisitions, consulting agreements, and changes in business focus. These items provide insight into how Fuse Group Holding Inc. presents its strategy, diversification efforts and partnerships over time. For investors and observers, following these announcements can help clarify the company’s stated direction in mining, biotech and consulting-related activities.
Summary not available.
Fuse Group Holding Inc. (OTCQB: FUST) announced a letter of intent to acquire E-Mo Biotech Holding Inc. for $100 million, payable in common stock at $1.00 per share. The acquisition will allow Fuse to enter the biotech sector, focusing on vaccine and treatment development, particularly against SARS-CoV-2. E-Mo is currently applying for FDA approval for a phase 4 clinical trial using an existing polio vaccine for COVID-19. This strategic move aims to aid in pandemic control while expanding Fuse's operational landscape within biotechnology.